Navigation Links
Canadian researchers find potential new leukemia treatment with old antibiotic drug
Date:11/14/2011

(Toronto Nov. 14, 2011) Clinician-scientists in the Princess Margaret Cancer Program have found a promising approach to treating leukemia, using an old drug in a new way.

The proof-of-concept research published today in Cancer Cell (10.1016/j.ccr.2011.10.015) describes how the Canadian team discovered that the antibiotic tigecycline targets and destroys leukemia stem cells by cutting off the cell's energy production.

"If you think of all the cells in the body as a power grid, we've discovered that tigecycline can cause a power outage in leukemia stem cells, while still keeping the lights on in all the healthy cells," says Dr. Aaron Schimmer, clinician-scientist at the Campbell Family Institute for Cancer Research in the Princess Margaret Cancer Program, University Health Network. He is also an associate professor in the departments of medicine, medical biophysics, and Institute of Medical Science at the University of Toronto (U of T).

To identify known drugs with previously unrecognized ability to kill leukemia cells and leukemia stem cells, the scientific team amassed a library of hundreds of known drugs to try, including tigecycline an intravenous antibiotic normally used to treat skin and abdominal infections. A high-speed, pipette-handling robot tested varying doses of each drug to see if any affected leukemia cells.

"Technology made this discovery possible. In three days, we found which potential leukemia drugs might be hiding in plain sight," says Dr. Schimmer. "Sifting through every combination by hand would have taken months."

"We tested more than 500 existing drugs on leukemia. Of the handful that made an impact, tigecycline was the most potent and revealed novel insights into the biology of leukemia at a cellular level," says lead author, Marko krtić, an MD/PhD student in the Faculty of Medicine at U of T, completing his PhD studies in Dr. Schimmer's lab.

The Canadian team demonstrated that leukemia cells have unique energy requirements and it is possible to selectively shut down this energy production in leukemia cells by blocking protein synthesis in the mitochondria.

By looking for new treatments in approved drugs, cancer researchers may be able to rapidly test these new strategies in patients, says Dr. Schimmer, who is now beginning multi-centre clinical trials with tigecycline as a treatment for leukemia.


'/>"/>

Contact: Geoff Koehler
geoff.koehler@uhn.ca
416-340-4011
University Health Network
Source:Eurekalert

Related medicine news :

1. Heart transplant surgery safe and effective: A Canadian retrospective spanning 3 decades
2. Canadian Journal of Cardiology publishes report on delayed vs. immediate coronary stenting
3. How hemp got high: Canadian scientists map the cannabis genome
4. Fatal crashes in the US: Fewer Canadian drivers under the influence
5. Skin color matters when it comes to Canadians health: UBC study
6. Most Canadians can be uniquely identified from their date of birth and postal code
7. US physician practices spend 4 times Canadian practices
8. US physicians spend nearly 4 times more on health insurance costs than Canadian counterparts
9. New Canadian blood pressure education program a powerful tool in fight to reduce stroke
10. Medicare improved Canadian doctors salaries: Queens University study
11. Canadians should demand commitments for pharmacare program, says CMAJ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... CA (PRWEB) , ... April 25, 2017 , ... ... access, support, and collaboration, announces Mirroring360 Pro . This new addition to ... comprehensive collaboration experience for education and business. , Mirroring360 Pro enables educators, business ...
(Date:4/25/2017)... Indianapolis, IN (PRWEB) , ... April 25, 2017 ... ... Washington, D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration ... Life Financial will provide insight into what changes are most likely to make ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients ... that achieves results in a fraction of the time as traditional braces – ... Significance Dental Specialists, now offers this revolutionary treatment with or without a referral. ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving multi-billion ... head shops –can’t help but be heartened by the industry’s current surge. But another ... described as “skunk smell.” At last they can simply, safely and effectively end ...
(Date:4/25/2017)... Fl (PRWEB) , ... April 25, 2017 , ... There ... Memorial Regional Hospital, according to a special report in the May issue of Consumer ... its highest quality ranking for results achieved during and after coronary bypass and ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Eyevensys, a private biotechnology company developing its ... that enables the safe, local, sustained production of therapeutic ... of ophthalmic diseases, announces it has received approval from ... to advance its technology into clinical development. ... The EyeCET platform uses ...
(Date:4/19/2017)... -- The Mobile X-Ray product segment is the most attractive ... forecast period Mobile X-Ray segment is the largest ... devices market, which is estimated to be valued at more ... of 7% over the forecast period. Mobile X-Ray segment is ... 100 Mn in 2017 over 2016. The segment,s revenue in ...
(Date:4/19/2017)... , April 19, 2017 The Global ... Forecast to 2022 report has covered and analysed the potential ... information on market size, shares and growth factors. The report ... challenges and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major ...
Breaking Medicine Technology: